Long Shot: Revance’s RT002 May Banish Frown Lines for 7 Months
Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.
Tag: Dermatologic Surgery
All
LatestSorry, No Posts Found
All
Latest
Stanford Appoints New Chief of Plastic and Reconstructive Surgery
A Stanford-trained microsurgeon will lead the division starting Sept 1, marking a leadership transition after two decades under the current chief.
